



16 December 2025

ASX ANNOUNCEMENT

CONNEQT Health December Quarter Sales Update

CONNEQT Health Limited (ASX: CQT) (“CONNEQT” or “the Company”) is pleased to provide an update on sales of its CONNEQT Pulse arterial health monitor for the December 2025 quarter.

Following strong momentum throughout FY25 and into the first half of FY26, Pulse sales in the December quarter are tracking ahead of internal expectations and exceeding the forecasts provided at the Company’s Annual General Meeting in November.

Sales Performance Ahead of Expectations

Key highlights for the December Quarter include:

- Sales revenue and unit sales are on track to exceed the strong 200% quarter-on-quarter sales growth outlined at the November AGM.
- Multiple record daily sales were achieved during the period alongside a significant increase in sales over the Black Friday weekend.
- Advertising and customer acquisition costs have been lower than forecast, reflecting continued improvements in marketing efficiency and conversion rates.
- Promising early uptake of Care+ subscription plans via the CONNEQT app, supporting the Company’s strategy to build recurring, subscription-based revenue streams across the CONNEQT ecosystem.

These results demonstrate continued acceleration in consumer adoption of the Pulse device and growing interest in CONNEQT’s clinical-grade cardiovascular insights. The Company expects this momentum to continue into the March quarter, supported by expanding marketing initiatives, seasonal demand influences and the strengthening of CONNEQT’s brand presence in the U.S. consumer health market.

Craig Cooper, CEO, CONNEQT Health commented:

“We are very pleased to see Pulse sales continuing to outperform expectations, with revenue and unit sales now exceeding the strong growth forecast we provided at the AGM.”

C O N N E Q T.
Health

CONNEQT Health, LTD.
ASX: CQT

Info@conneqthealth.com
conneqthealth.com

Suite 301, 55 Lime St
Sydney NSW 2000
Australia

+61 2 9874 8761



With sales accelerating, acquisition costs declining and early subscription revenue building, CONNEQT enters the second half of FY26 with strong commercial momentum. The Company remains focused on expanding marketing efficiency, increasing subscription adoption and scaling production to support ongoing demand.

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations

Rod Hinchcliffe

rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton

melissa.hamilton@mcpartners.com.au

About CONNEQT HEALTH

CONNEQT Health's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market-leading SphygmoCor® vascular biomarker technology. CONNEQT Health is listed on the Australian Stock Exchange ("ASX: CQT").